Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$466.01 ▲ +5.28
(+1.15%)
MKT CAP: $249.09B • VOL: 3.29M
52W L $292 52W H $476
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$391
MEDIAN
$522
MEAN
$531
HIGH
$634
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AMGN TAPE
AMGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $563.87 | $535.91 | 2025-02-14 | $424.07 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $587.17 | $549.89 | 2025-02-06 | $438.05 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $531.25 | $512.61 | 2025-01-29 | $447.37 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $475.33 | — | 2025-01-17 | $456.69 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $410.09 | $442.71 | 2025-01-09 | $414.75 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $554.55 | $484.65 | 2024-12-18 | $405.43 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $452.03 | $470.67 | 2024-12-04 | $433.39 | -4.3% | 48% | C |